Editas Medicine, Inc. announced that James C. Mullen, the Executive Chairman of the Board of Directors notified the Board that he does not intend to seek re-election as a director of the Company when his current term ends at the 2023 Annual Meeting of Stockholders.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.615 USD | -4.67% | +5.73% | -44.47% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.47% | 484M | |
+32.73% | 50.85B | |
+0.07% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.83% | 26.11B | |
-22.26% | 19.13B | |
+8.37% | 13.05B | |
+27.21% | 12.16B | |
+24.42% | 12.08B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Medicine, Inc. Announces That James C. Mullen, the Executive Chairman of the Board of Directors Will Not Stand for Re-Election as A Director